Annual Cash & Cash Equivalents
$4.28 M
+$1.30 M+43.65%
December 31, 2023
Summary
- As of February 7, 2025, CANF annual cash & cash equivalents is $4.28 million, with the most recent change of +$1.30 million (+43.65%) on December 31, 2023.
- During the last 3 years, CANF annual cash & cash equivalents has fallen by -$3.99 million (-48.26%).
- CANF annual cash & cash equivalents is now -74.71% below its all-time high of $16.91 million, reached on December 31, 2015.
Performance
CANF Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$4.72 M
+$441.00 K+10.31%
June 30, 2024
Summary
- As of February 7, 2025, CANF quarterly cash and cash equivalents is $4.72 million, with the most recent change of +$441.00 thousand (+10.31%) on June 30, 2024.
- Over the past year, CANF quarterly cash and cash equivalents has increased by +$1.26 million (+36.47%).
- CANF quarterly cash and cash equivalents is now -72.10% below its all-time high of $16.91 million, reached on December 1, 2015.
Performance
CANF Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CANF Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +43.6% | +36.5% |
| 3 y3 years | -48.3% | +360.4% |
| 5 y5 years | +18.3% | -42.5% |
CANF Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -2.5% | +43.6% | -14.3% | +273.3% |
| 5 y | 5-year | -48.3% | +58.6% | -53.8% | +360.4% |
| alltime | all time | -74.7% | +273.6% | -72.1% | +888.9% |
Can-Fite BioPharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2024 | - | $4.72 M(+10.3%) |
| Dec 2023 | $4.28 M(+43.7%) | $4.28 M(+26.5%) |
| Sep 2023 | - | $3.38 M(-2.2%) |
| Jun 2023 | - | $3.46 M(+173.6%) |
| Mar 2023 | - | $1.26 M(-57.6%) |
| Dec 2022 | $2.98 M(-32.2%) | $2.98 M(-20.1%) |
| Sep 2022 | - | $3.73 M(+117.7%) |
| Jun 2022 | - | $1.71 M(-68.9%) |
| Mar 2022 | - | $5.50 M(+25.4%) |
| Dec 2021 | $4.39 M(-46.9%) | $4.39 M(-24.4%) |
| Sep 2021 | - | $5.81 M(+466.4%) |
| Jun 2021 | - | $1.02 M(-62.6%) |
| Mar 2021 | - | $2.74 M(-66.8%) |
| Dec 2020 | $8.27 M(+206.6%) | $8.27 M(-19.1%) |
| Sep 2020 | - | $10.22 M(+12.8%) |
| Jun 2020 | - | $9.06 M(+235.9%) |
| Dec 2019 | $2.70 M(-25.4%) | - |
| Dec 2019 | - | $2.70 M(-42.4%) |
| Sep 2019 | - | $4.68 M(-42.9%) |
| Jun 2019 | - | $8.20 M(+177.5%) |
| Mar 2019 | - | $2.96 M(-18.2%) |
| Dec 2018 | $3.62 M(+3.1%) | - |
| Dec 2018 | - | $3.62 M(-36.9%) |
| Sep 2018 | - | $5.73 M(-1.9%) |
| Jun 2018 | - | $5.84 M(-29.8%) |
| Mar 2018 | - | $8.31 M(+137.2%) |
| Dec 2017 | $3.50 M | - |
| Dec 2017 | - | $3.50 M(-31.3%) |
| Sep 2017 | - | $5.10 M(-25.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $6.88 M(-29.7%) |
| Mar 2017 | - | $9.78 M(+20.5%) |
| Dec 2016 | $8.11 M(-52.0%) | - |
| Dec 2016 | - | $8.11 M(-18.9%) |
| Sep 2016 | - | $10.01 M(-16.9%) |
| Jun 2016 | - | $12.04 M(-19.6%) |
| Mar 2016 | - | $14.97 M(-11.5%) |
| Dec 2015 | $16.91 M(+82.5%) | - |
| Dec 2015 | - | $16.91 M(+17.2%) |
| Sep 2015 | - | $14.44 M(+86.9%) |
| Jun 2015 | - | $7.73 M(-14.3%) |
| Mar 2015 | - | $9.02 M(-2.7%) |
| Dec 2014 | $9.27 M(+55.4%) | - |
| Dec 2014 | - | $9.27 M(+124.5%) |
| Sep 2014 | - | $4.13 M(-26.1%) |
| Jun 2014 | - | $5.59 M(-28.6%) |
| Mar 2014 | - | $7.83 M(+31.3%) |
| Dec 2013 | $5.96 M(+420.8%) | $5.96 M(+120.0%) |
| Sep 2013 | - | $2.71 M(-15.3%) |
| Jun 2013 | - | $3.20 M(-39.1%) |
| Mar 2013 | - | $5.25 M(+358.5%) |
| Dec 2012 | $1.15 M(-70.2%) | - |
| Dec 2012 | - | $1.15 M(-40.1%) |
| Sep 2012 | - | $1.91 M(-28.2%) |
| Jun 2012 | - | $2.66 M(-3.4%) |
| Mar 2012 | - | $2.75 M(-28.3%) |
| Dec 2011 | $3.84 M | - |
| Dec 2011 | - | $3.84 M(+705.1%) |
| Sep 2011 | - | $477.20 K |
FAQ
- What is Can-Fite BioPharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Can-Fite BioPharma?
- What is Can-Fite BioPharma annual cash & cash equivalents year-on-year change?
- What is Can-Fite BioPharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Can-Fite BioPharma?
- What is Can-Fite BioPharma quarterly cash and cash equivalents year-on-year change?
What is Can-Fite BioPharma annual cash & cash equivalents?
The current annual cash & cash equivalents of CANF is $4.28 M
What is the all time high annual cash & cash equivalents for Can-Fite BioPharma?
Can-Fite BioPharma all-time high annual cash & cash equivalents is $16.91 M
What is Can-Fite BioPharma annual cash & cash equivalents year-on-year change?
Over the past year, CANF annual cash & cash equivalents has changed by +$1.30 M (+43.65%)
What is Can-Fite BioPharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CANF is $4.72 M
What is the all time high quarterly cash and cash equivalents for Can-Fite BioPharma?
Can-Fite BioPharma all-time high quarterly cash and cash equivalents is $16.91 M
What is Can-Fite BioPharma quarterly cash and cash equivalents year-on-year change?
Over the past year, CANF quarterly cash and cash equivalents has changed by +$1.26 M (+36.47%)